Skip to main content

Alzheimer's Disease: Challenges for the next decade

Neuron cell system shown in blue

  1. Alzheimer’s disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration. Extensive clinical and genomic studies have revealed biomarkers, risk fact...

    Authors: Minghui Wang, Won-min Song, Chen Ming, Qian Wang, Xianxiao Zhou, Peng Xu, Azra Krek, Yonejung Yoon, Lap Ho, Miranda E. Orr, Guo-Cheng Yuan and Bin Zhang
    Citation: Molecular Neurodegeneration 2022 17:17
  2. Mass spectrometry-based proteomics empowers deep profiling of proteome and protein posttranslational modifications (PTMs) in Alzheimer’s disease (AD). Here we review the advances and limitations in historic an...

    Authors: Bing Bai, David Vanderwall, Yuxin Li, Xusheng Wang, Suresh Poudel, Hong Wang, Kaushik Kumar Dey, Ping-Chung Chen, Ka Yang and Junmin Peng
    Citation: Molecular Neurodegeneration 2021 16:55

    The Correction to this article has been published in Molecular Neurodegeneration 2021 16:72

  3. Alzheimer disease (AD) prevention trials hold the promise to delay or prevent cognitive decline and dementia onset by intervening before significant neuronal damage occurs. In recent years, the first AD preven...

    Authors: Eric McDade, Jorge J. Llibre-Guerra, David M. Holtzman, John C. Morris and Randall J. Bateman
    Citation: Molecular Neurodegeneration 2021 16:49
  4. Neuropsychiatric symptoms (NPSs) are common in patients with Alzheimer’s disease (AD) and are associated with accelerated cognitive impairment and earlier deaths. This review aims to explore the neural pathoge...

    Authors: Yaojing Chen, Mingxi Dang and Zhanjun Zhang
    Citation: Molecular Neurodegeneration 2021 16:38
  5. Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder that is characterized by neurodegeneration, cognitive impairment, and an eventual inability to perform daily tasks. The etiology of Alzheim...

    Authors: Mabel Seto, Rebecca L. Weiner, Logan Dumitrescu and Timothy J. Hohman
    Citation: Molecular Neurodegeneration 2021 16:29
  6. Alzheimer’s disease (AD) is the most common type of dementia, affecting millions of people worldwide; however, no disease-modifying treatments are currently available. Genome-wide association studies (GWASs) h...

    Authors: Gloriia Novikova, Shea J. Andrews, Alan E. Renton and Edoardo Marcora
    Citation: Molecular Neurodegeneration 2021 16:27
  7. Alzheimer’s disease (AD) is among the most prevalent neurodegenerative diseases, with brain pathology defined by extracellular amyloid beta deposits and intracellular tau aggregates. To aid in research efforts...

    Authors: Brittany S. Ulm, David R. Borchelt and Brenda D. Moore
    Citation: Molecular Neurodegeneration 2021 16:8
  8. Successful development of agents that improve cognition and behavior in Alzheimer’s disease (AD) is critical to improving the lives of patients manifesting the symptoms of this progressive disorder.

    Authors: Jeffrey Cummings
    Citation: Molecular Neurodegeneration 2021 16:2

    The Correction to this article has been published in Molecular Neurodegeneration 2021 16:21

  9. Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for Alzheimer’s disease (AD), have yielded significant insights into the pathogenic mechanism. Among the three common coding variant...

    Authors: Zonghua Li, Francis Shue, Na Zhao, Mitsuru Shinohara and Guojun Bu
    Citation: Molecular Neurodegeneration 2020 15:63
  10. Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer’s disease (AD) continuum. Investigating populations with SCD is important for understanding the early patholo...

    Authors: Xiaoqi Wang, Weijie Huang, Li Su, Yue Xing, Frank Jessen, Yu Sun, Ni Shu and Ying Han
    Citation: Molecular Neurodegeneration 2020 15:55
  11. Alzheimer disease (AD) is the most prominent form of dementia and the 5th leading cause of death in individuals over 65. AD is a complex disease stemming from genetic, environmental, and lifestyle factors. It ...

    Authors: Hannah R. Bulgart, Evan W. Neczypor, Loren E. Wold and Amy R. Mackos
    Citation: Molecular Neurodegeneration 2020 15:42
  12. Alzheimer’s disease (AD) is the most common neurodegenerative disorder seen in age-dependent dementia. There is currently no effective treatment for AD, which may be attributed in part to lack of a clear under...

    Authors: Tiantian Guo, Denghong Zhang, Yuzhe Zeng, Timothy Y. Huang, Huaxi Xu and Yingjun Zhao
    Citation: Molecular Neurodegeneration 2020 15:40
  13. Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by impaired cognitive function due to progressive loss of neurons in the brain. Under the microscope, neuronal ac...

    Authors: Wenzhang Wang, Fanpeng Zhao, Xiaopin Ma, George Perry and Xiongwei Zhu
    Citation: Molecular Neurodegeneration 2020 15:30